Oh dear !!, page-43

xc

like i mentioned earlier . not competing with ssh or with lvads. our main focus is grade 3 hf with a portion of grade 4 . so far our competition for grade 3 hf is no one. hence , the addressing the market and cardiologists and patients that they are indeed sick and in need of a solution rather than doing nothing and letting their condition deteriorate.

concerning lvads , if cpulse proves its efficiency , it will spell trouble to lvads as we will take a portion of their market share. more affordable less invasive less risk no blood contact + cpulse 2 on the way ?

happy with the structure of the company , I feel dave has done a remarkable job on all fronts . financing , appointments , media presence .

the share price doesnt reflect the great work the company has been making.

lots of potential milestones coming up hopefully

- higher enrollments
- german reimbursement
- euro distribution deal ?
- fda interim analysis approval
- buyout rumors edwards ?
- cpulse 2 first human implant ?

all the best